| 崔艳艳,綦会霞,常桂花,房 芹,王亚丽,王玉敏,伍 婕.艾迪注射液联合化疗对卵巢癌患者血清HE4，CA125，CA19-9，AFP，CEA水平及T细胞亚群的影响[J].现代生物医学进展英文版,2017,17(21):4082-4085. |
| 艾迪注射液联合化疗对卵巢癌患者血清HE4，CA125，CA19-9，AFP，CEA水平及T细胞亚群的影响 |
| Effect of Aidi Injection Combined with Chemotherapy on Serum Levels of HE4, CA125, CA19-9, AFP and CEA and T Cell Subsets of Patients with Ovarian Cancer |
| Received:December 19, 2016 Revised:January 13, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.21.020 |
| 中文关键词: 艾迪注射液 卵巢癌 人附睾蛋白4 糖类抗原125 糖类抗原19-9 甲胎蛋白 癌胚抗原 T细胞亚群 |
| 英文关键词: Aidi injection Chemotherapy Ovarian cancer HE4 CA125 CA19-9 AFP CEA T cell subsets |
| 基金项目:内蒙古自然科学基金重点项目(8k62538) |
|
| Hits: 446 |
| Download times: 247 |
| 中文摘要: |
| 摘要 目的：探讨艾迪注射液联合化疗对卵巢癌患者血清人附睾蛋白4(HE4)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、甲胎蛋白(AFP)、癌胚抗原(CEA)及T细胞亚群的影响。方法：选取我院2014年8月至2016年2月收治的78例卵巢癌患者，按照随机数表法将其分为观察组(n=39)和对照组(n=39)，对照组患者给予化疗，观察组患者给予艾迪注射液联合化疗，比较两组患者的临床疗效、治疗前后血清HE4、CA125、CA19-9、AFP、CEA水平及T细胞亚群的变化。结果：治疗后，观察组的总有效率(94.87%)显著高于对照组(76.92%) (P<0.05)。治疗后，两组患者血清HE4、CA125、CA19-9、AFP、CEA水平均较治疗前明显下降，且观察组显著低于对照组(P<0.05)。治疗后，两组患者CD3+、CD4+、CD8+较治疗前均显著降低，且观察组患者CD3+、CD4+、CD8+低于对照组(P<0.05)。结论：艾迪注射液联合化疗对卵巢癌治疗效果显著，能有效降低血清HE4、CA125、CA19-9、AFP、CEA水平并改善患者免疫功能。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of Aidi injection combined with chemotherapy on the serum levels of HE4, CA125, CA19-9, AFP, CEA and T cell subsets in patients with ovarian cancer. Methods: 78 cases with ovarian cancer admitted in our hospital from August 2014 to February 2016 were selected and randomly divided into the observation group (n=39) and the control group (n=39). The patients in the control group were treated with chemotherapy, and the patients in the observation group were treated with aidi injec- tion combined with chemotherapy. Then the clinical effect, the serum levels of HE4, CA125, CA19-9, AFP, CEA and T cell subsets be- tween the two groups were observed and compared before and after the treatment. Results: The total effective rate in the observation group was 94.87%, which was higher than that of the control group (P<0.05). The serum levels of HE4, CA125 and CA19-9 in the two groups after treatment were lower than before, and the the observation group was lower than that of the control group (P<0.05). The serum levels of AFP and CEA of patients in the two groups after treatment were significantly lower than before, and the observation group was lower than that of the control group (P<0.05). The ratio of CD3+, CD4+ and CD8+ in the two groups after treatment were signif- icantly lower than before, and the observation group was significantly lower than that of the control group (P<0.05). Conclusion: Aidi in- jection combined with chemotherapy has remarkable clinical effects on the treatment of ovarian cancer, which can reduce the serum levels of CA125, CA19-9, AFP, CEA and T cell subsets, and improve the immune functions of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
